Jianmin Wu

Eli Lilly and Company

Poster(s):

• P4398 - The Impact of Mirikizumab Induction, Maintenance, and Long-Term Treatment on Disease Clearance in Patients With Moderately to Severely Active Ulcerative Colitis: Post-Hoc Analysis of LUCENT Trials
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET